Head-to-head evidence
AB801 vs CAB-AXL-ADC
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: AXL · full Non-Small Cell Lung Cancer pipeline
AB801
Developed by Arcus Biosciences
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
CAB-AXL-ADC
Developed by BioAtla, Inc.
NCT04681131 · Phase 2 · completed
The study was nonrandomized and open-label, with two experimental treatment groups and no placebo or active comparator. Its primary efficacy endpoint was objective tumor response assessed by RECIST. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AB801's landscape · CAB-AXL-ADC's landscape